

1 **Manuscript title:** Loss expansion of SARS-CoV-2 specific immunity is a key risk factor in fatal
2 patients with COVID-19

3

4 Qiang Zeng, MD[#], Gang Huang, MD[#], Yong-zhe Li, MD[#], Guoqiang Xu, PhD, Sheng-yong Dong,
5 MD, Tian-yu Zhong, MD, Zong-tao Chen, MD, Yang Xu, MD, PhD^{*}

6 **Authors' name and affiliations:**

7 Chinese PLA General Hospital, Beijing, China (Q. Zeng, S.Y. Dong); Shanghai University of
8 Medicine and Health Sciences, Shanghai, China (G. Huang, Y. Xu); Jiangsu Key Laboratory of
9 Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China
10 (G. Xu); First Affiliated Hospital, Gannan Medical University, Ganzhou, China (T.Y. Zhong); The
11 first affiliated Hospital, Army Medical University, Chongqing, China (Z.T. Chen); Department of
12 Laboratory Medicine, Peking Union Medical College Hospital, Beijing, China (Y.Z. Li).

13

14 *** Contact information for the corresponding author:**

15 Yang Xu, MD, PhD, Director

16 Laboratory of Special Diagnosis

17 Shanghai University of Medicine and Health Sciences

18 Shanghai 201318, China

19 E-mail: yxu1627@126.com

20

21

22 **Highlights**

23

24 ● **The immune system and function have gradually remodeled and declined with age**

25 ● **SARS-CoV-2 specific immunity has declined with age in fatal cases**

26 ● **SARS-CoV-2 specific immunity is associated with survival time in fatal cases**

27 ● **The loss expansion of SARS-CoV-2 specific immunity could be expanded *in vitro***

28 ● **A concurrent decline in SARS-CoV-2 specific cellular and humoral immunity and**

29 **prolonged SARS-CoV-2 exposure predicted fatal outcomes**

30

31

32

33

34

35

36

37

38

39

40

41

42 **Keywords**

43 CD4; CD8; COVID-19; Expansion; IFN γ ; SARS-CoV-2 specific immunity; SARS-CoV-2; T cells

44 **ABSTRACT**

45 The dynamic immunological characteristics of COVID-19 patients are essential for clinicians to
46 understand the disease progression. Our data showed that the immune system and function have
47 gradually remodeled and declined with age from 16-91 years old in 25,239 healthy controls.
48 Analyzing the relationship between the number of lymphocytes and age showed that lymphocytes
49 and subsets tended to decline with age significantly, whereas, the number of natural killer cells
50 tended to increase with age significantly. SARS-CoV-2 specific immunity has declined with age in
51 fatal cases. Furthermore, SARS-CoV-2 specific immunity is associated with survival time in fatal
52 cases. The loss expansion of SARS-CoV-2 specific immunity could be expanded *in vitro*. A
53 concurrent decline in SARS-CoV-2 specific cellular and humoral immunity and prolonged
54 SARS-CoV-2 exposure predicted fatal outcomes. Our findings have provided a basis for further
55 analysis of SARS-CoV-2 specific immunity and understanding the pathogenesis of fatal
56 COVID-19 patients.

57

58

59

60

61

62

63

64

65

66

67 **INTRODUCTION**

68 Coronavirus disease 2019 (COVID-19) pandemic leads to severe illness, life-threatening
69 complications, and death, especially in high-risk groups such as elderly people and individuals
70 with comorbidities¹⁻⁷. However, information on immunological characteristics in the assessment
71 of COVID-19 for frontline clinicians is limited. The objective of this study is to explore the
72 dynamic immunological characteristics as the disease progresses.

73 In January, 2020, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was
74 identified in samples of bronchoalveolar lavage fluid from patients in Wuhan, China, and was
75 confirmed as the cause of the SARS-CoV-2 pneumonia^{1,2}. Full-genome sequencing and
76 phylogenetic analysis indicated that SARS-CoV-2 is a distinct clade from the betacoronaviruses
77 associated with human SARS and Middle East respiratory syndrome (MERS)^{1,2}.

78

79 COVID-19 has spread rapidly since it was first identified in Wuhan and has been shown to have a
80 wide spectrum of severity. Recently, a report shows that SARS-CoV and SARS-CoV-2 shared the
81 same functional host-cell receptor, angiotensin-converting enzyme 2 (ACE2)⁸. Furthermore,
82 SARS-CoV-2 binds to ACE2 receptors in 10-20 fold higher affinity than SARS-CoV binds to the
83 same receptors⁸. The receptor binding domain is recognized by the extracellular peptidase domain
84 of ACE2 mainly through polar residues, which provide important insights into the molecular basis
85 for coronavirus recognition and infection⁹. Since ACE2 receptors on lung alveolar epithelial cells
86 and enterocytes of the small intestine are highly expressed, lung alveolar epithelial cells or

87 enterocytes of the small intestine may be an important source of infection¹⁰.

88 According to World Health Organization (WHO) interim guidance on January 12, 2020,
89 SARS-CoV-2 infection is classified as asymptomatic, mild, severe, and critical cases of
90 pneumonia (acute respiratory distress syndrome [ARDS], sepsis, septic shock). Severe cases of
91 pneumonia are defined as patients with respiratory rate > 30 breaths/min, severe respiratory
92 distress, or peripheral capillary oxygen saturation < 90% on room air¹¹. Asymptomatic cases have
93 been reported in China and Germany^{12,13}. Huang et al.² first reported 41 cases of SARS-CoV-2
94 pneumonia in which most patients had a history of exposure to Huanan Seafood Wholesale
95 Market. Organ dysfunction (shock, ARDS, acute cardiac injury, and acute kidney injury, etc.) and
96 death can occur in severe or critical cases. Guan et al.³ reported findings from 1,099 cases of
97 SARS-CoV-2 pneumonia and the results suggested that the SARS-CoV-2 infection clustered
98 within groups of people in close contact, and was more likely to affect the old with comorbidities.
99 However, there is no pre-existing antibody-mediated immunity to SARS-CoV-2 at the population
100 level, leading to more than half million deaths and 10 millions of infections which have been
101 reported worldwide as of June 29, 2020¹⁴.

102 The disease severity is associated with immune dysregulation, for example, dysregulation of T
103 cells, or associated with macrophage activation syndrome¹⁵⁻²¹. Grifoni et al.²² reported
104 SARS-CoV-2-specific CD4 and CD8 T cells responses in 20 recovery cases of COVID-19. Using
105 multiple experimental approaches, SARS-CoV-2-specific CD4 T cell and antibody responses were
106 observed in all COVID-19 patients and SARS-CoV-2-specific CD8 T cell responses were seen in
107 most COVID-19 patients. All of the patients had SARS-CoV-2-specific CD4 T cells that

108 recognized the virus's spike protein, and 70% of them had SARS-CoV-2-specific CD8 T cells that
109 responded to the same protein. The identification of strong T cell responses in recovered
110 COVID-19 patients promotes further study in designing vaccines to induce T cell responses. Ni et
111 al.¹⁸ also observed SARS-CoV-2-specific humoral and cellular immunity in 14 convalescent
112 patients. However, to the best of our knowledge, SARS-CoV-2-specific CD4 and CD8 T cell
113 responses in fatal cases of COVID-19 were not reported. Furthermore, understanding the key
114 immune mechanisms to recover from novel SARS-CoV-2 exposure is an urgent need.

115 It is important to understand the key risk factors of critical patients who died. We hypothesize that
116 lethal COVID-19 disease would be associated with immune dysregulation and loss expansion of
117 SARS-CoV-2-specific immunity. Here, we analyzed dynamic immunological characteristics in
118 fatal COVID-19 patients in a unique longitudinal cohort of samples.

119 **RESULTS**

120 **The immune system and function have gradually remodeled and declined with age in 25,239** 121 **healthy controls**

122 The relationship between the number of lymphocytes and subsets and age showed that
123 lymphocytes and subsets except natural killer (NK) cells tended to decline with age significantly
124 (Figure 1A-E, Spearman $R = -[\text{range}, 0.08978-0.1950]$, $P < 0.0001$). However, the relationship
125 between NK cells and age showed that the number of NK cells tended to increase with age (Figure
126 1F, Spearman $R = 0.1188$, $P < 0.0001$) significantly, suggesting that NK cells, a component of the
127 innate immune system, expanded with age.

128 **SARS-CoV-2 specific immunity has declined with age in fatal COVID-19 patients**

129 The relationship between SARS-CoV-2 specific immunity and age showed that SARS-CoV-2
130 specific immunity tended to decline with age (Figure 2A-C). However, the relationship between
131 SARS-CoV-2 virus load and age showed that the virus load tended to increase with age (Figure
132 2D).

133 The ability to expand SARS-CoV-2 specific interferon gamma (IFN γ)+CD4+ T cells (Figure 2A,
134 Spearman R = -0.8020, $P < 0.0001$) and IFN γ +CD8+ T cells (Figure 2B, Spearman R = -0.8028,
135 $P < 0.0001$) was significantly inversely related to age. It suggested that the elderly was low in
136 expansion ability of SARS-CoV-2 specific T cell immunity, so it was easy to turn into severe
137 illness, which was an important risk factor for mortality in the elderly. SARS-CoV-2 specific
138 humoral immunity (Figure 2C, Spearman R = -0.2671, $P = 0.0254$) was also inversely related to
139 age. However, this relationship was weaker than that of SARS-CoV-2 specific T cell immunity.
140 SARS-CoV-2 viral load was directly proportional to age, which was significant (Figure 2D,
141 Spearman R = 0.4780, $P < 0.0001$). It suggested that the elderly were easily infected by the virus
142 or the patient had a higher viral load in the body.

143 **SARS-CoV-2 specific immunity is associated with survival time in fatal COVID-19 patients**

144 The relationship between SARS-CoV-2 specific immunity and survival time showed that as the
145 survival time increases, SARS-CoV-2 specific immunity tended to rise. However, the relationship
146 between virus load and survival time showed that the virus load tended to decrease as the survival
147 time increases (Figure 3).

148 The correlation between SARS-CoV-2 specific IFN γ +CD4+ T cells (Figure 3A, Spearman R =
149 0.7655, $P < 0.0001$) and IFN γ +CD8+ T cells (Figure 3B, Spearman R = 0.7623, $P < 0.0001$) and

150 survival time was relatively strong, and significantly correlated with survival time, suggesting that
151 patient survival time depended on the expansion ability of SARS-CoV-2 specific T cell immunity.
152 The aggregated data for 4 weeks showed that SARS-CoV-2 specific humoral immunity was
153 related to survival time significantly (Figure 3C, Spearman $R = 0.7924$, $P < 0.0001$).
154 SARS-CoV-2 viral load was inversely proportional to survival time significantly (Figure 3D,
155 Spearman $R = -0.4730$, $P < 0.0001$). It suggested that the higher the viral load of SARS-CoV-2,
156 the shorter the survival time of patients. Therefore, controlling the replication of the virus might
157 prolong the survival time of patients.
158 There was no significant difference in the frequency of SARS-CoV-2 specific $IFN\gamma+CD4+$ T cells
159 (Figure 4A) between the first week and the second week. However, there were significant
160 differences between the first week and the third or fourth week, suggesting that SARS-CoV-2
161 specific $IFN\gamma+CD4+$ T cells began to expand in the third week significantly (Figure 4A). There
162 was no significant difference in the frequency of SARS-CoV-2 specific $IFN\gamma+CD8+$ T cells
163 between the first week and the second, third, or fourth week, indicating that the expansion of
164 specific CD8 T cells were lost (Figure 4B). There was a significant difference between the titer of
165 specific IgG antibodies in the first week and the second week. Compared to the first week, the IgG
166 titer in week 2-4 continued to show significant differences, suggesting that SARS-CoV-2 specific
167 antibodies began to expand in the second week, but the antibody titer was low (Figure 4C). There
168 was a significant difference between the viral load from week 1 to week 4 (Figure 4D), suggesting
169 that SARS-CoV-2 specific immunity could clear SARS-CoV-2 replication in fatal cases. However,
170 the SARS-CoV-2 specific immunity was unable to clear all SARS-CoV-2 in fatal cases. The mean
171 viral load was 6.7×10^4 copies/mL at week 3, indicating the presence of persistent SARS-CoV-2

172 infection.

173

174 **The loss expansion of SARS-CoV-2 specific immunity in fatal cases could be expanded *in***

175 ***vitro***

176 From the above results, it can be known that the key factor was the loss expansion of

177 SARS-CoV-2 specific humoral and cellular immunity and the virus cannot be eliminated from the

178 body in fatal cases. Since the expansion of SARS-CoV-2 specific immunity started from the first

179 2-3 weeks, we chose PMBCs in the third week for the expansion experiment *in vitro*. Our data

180 showed that these PBMCs could be expanded *in vitro*. After the expansion, SARS-CoV-2 specific

181 IFN γ +CD4⁺ T cells and IFN γ +CD8⁺ T cells increased significantly (Figure 5). It suggested that

182 the SARS-CoV-2 specific immunity of these 21 fatal patients lost their expansion at week 3, but

183 the expansion of SARS-CoV-2 specific cellular immunity could be recovered *in vitro* experiment

184 (Figure 5).

185 **A concurrent decline in SARS-CoV-2 specific cellular and humoral immunity and prolonged**

186 **SARS-CoV-2 exposure predicted fatal outcomes**

187 There was significant correlation between SARS-CoV-2 specific IFN γ +CD4⁺ T cells (Figure 6A,

188 Spearman R = 0.4537, $P < 0.0001$) and IFN γ +CD8⁺ T cells (Figure 6B, Spearman R = 0.3721, P

189 = 0.0002) and SARS-CoV-2 specific humoral immunity.

190 SARS-CoV-2 specific IFN γ +CD4⁺ T cells (Figure 7A, Spearman R = -0.4784, $P < 0.0001$) and

191 IFN γ +CD8⁺ T cells (Figure 7B, Spearman R = -0.4609, $P < 0.0001$) inversely correlated with

192 SARS-CoV-2 viral load significantly, suggesting that SARS-CoV-2 specific T cell immunity plays

193 a leading role in virus clearance. However, the frequency of SARS-CoV-2 specific T cells was

194 significantly lower than that of survival patients with COVID-19 (Figure 9A, 9B), suggesting that
195 loss expansion of SARS-CoV-2 specific cellular immunity in fatal cases.

196 SARS-CoV-2 specific humoral immunity inversely correlated with SARS-CoV-2 viral load
197 significantly, suggesting that SARS-CoV-2 specific humoral immunity played a role in virus
198 clearance (Figure 8). However, the R number of SARS-CoV-2 specific humoral immunity was
199 smaller than that of SARS-CoV-2 specific T cell immunity (Figure 7, Figure 8), suggesting that
200 SARS-CoV-2 specific T cell immunity might play a major role in virus clearance in fatal cases. In
201 addition, the IgG titer was significantly lower than that of survival patients with COVID-19
202 (Figure 9C), suggesting that loss expansion of SARS-CoV-2 specific humoral immunity in fatal
203 cases.

204 However, the SARS-CoV-2 specific immunity was unable to clear SARS-CoV-2 in fatal cases. All
205 patients were detected positive viral load before death, suggesting that prolonged SARS-CoV-2
206 exposure predicted fatal outcomes (Figure 4D).

207 **DISCUSSION**

208 The extent of lymphopenia in patients admitted to the intensive care unit correlates with
209 COVID-19 severity and mortality²³⁻²⁶. Therefore, studies of the immune system and function in
210 healthy controls are important to understand whether the immune system and function is related to
211 age. Our data showed that the immune system and function have gradually remodeled and
212 declined with age in 25,239 healthy controls.

213 Channappanavar et al.²⁷ reported that SARS-CoV-specific memory CD8 T cells persisted for up to
214 6 years after SARS-CoV infection. When challenge with a lethal dose of SARS-CoV,
215 virus-specific memory CD8 T cells efficiently produced IFN γ , tumor necrosis factor α (TNF- α),

216 etc. and reduced lung viral load. Next, we tried to understand whether SARS-CoV-2 specific
217 immunity is associated with age in those fatal patients with COVID-19. Our data suggested that
218 SARS-CoV-2 specific immunity has declined with age in COVID-19 patients.

219 Levels of lymphocytes and lymphocyte subsets are of great importance to keep the immune
220 system working. Usually viral infection, immunodeficiency diseases, and other infectious diseases
221 lead to abnormal changes in the levels of lymphocyte subsets¹⁶. Although SARS-CoV-2 has been
222 identified as the causative agent of COVID-19, the mechanism by which SARS-CoV-2 impacts
223 the human immune system is still unclear¹⁶.

224 Grifoni et al.²² reported SARS-CoV-2-specific CD4 and CD8 T cells responses in 20 recovery
225 cases of COVID-19. SARS-CoV-2-specific CD4 T cell and antibody responses were observed in
226 all COVID-19 patients and SARS-CoV-2-specific CD8 T cell responses were seen in most
227 COVID-19 patients. Ni et al.¹⁸ also observed SARS-CoV-2-specific humoral and cellular
228 immunity in 14 convalescent patients. We explored whether SARS-CoV-2 specific immunity is
229 associated with survival time in those fatal patients with COVID-19. Our data showed that
230 SARS-CoV-2 specific immunity was associated with survival time in COVID-19 patients. Our
231 results were consistent with previous reports^{18,22}.

232 From the above results, it can be known that the key factor was the loss expansion of
233 SARS-CoV-2 specific humoral and cellular immunity and the virus cannot be eliminated from the
234 body in fatal cases. We tried to understand whether the loss expansion of SARS-CoV-2 specific
235 immunity in fatal cases could be expanded *in vitro*. Since the expansion of SARS-CoV-2 specific
236 immunity started from the first 2-3 weeks, we chose PMBCs in the third week for the expansion

237 experiment *in vitro*. Our data showed that these PBMCs could be expanded *in vitro*. After the
238 expansion, SARS-CoV-2 specific IFN γ +CD4⁺ T cells and IFN γ +CD8⁺ T cells increased
239 significantly. It suggested that the SARS-CoV-2 specific immunity of these fatal patients lost their
240 expansion, but the expansion of SARS-CoV-2 specific cellular immunity could be recovered *in*
241 *vitro* experiment.

242 Our data indicated that a concurrent decline in SARS-CoV-2 specific cellular and humoral
243 immunity and prolonged SARS-CoV-2 exposure predicted fatal outcomes. First, the immune
244 system and function have gradually remodeled and declined with age in healthy controls.
245 Therefore, the elderly are susceptible to the SARS-CoV-2. Second, our data showed that
246 SARS-CoV-2 specific immunity has declined with age in COVID-19 patients. Therefore, the
247 elderly easily turned from mild to severe SARS-CoV-2 infections. Those results have explained
248 that the elderly is a risk factor for poor outcomes. Third, our data further showed that
249 SARS-CoV-2 specific immunity is associated with survival time in COVID-19 patients. The
250 correlation between SARS-CoV-2 specific IFN γ +CD4⁺ T cells and IFN γ +CD8⁺ T cells and
251 survival time was relatively strong, and significantly correlated with survival time, suggesting that
252 patient survival time depended on the expansion ability of SARS-CoV-2 specific T cell immunity.
253 The aggregated data for 4 weeks showed that SARS-CoV-2 specific humoral immunity was
254 related to survival time. SARS-CoV-2 viral load was inversely proportional to survival time
255 significantly. It suggested that the higher the viral load of SARS-CoV-2, the shorter the survival
256 time of patients. Therefore, controlling the replication of the virus might prolong the survival time
257 of patients. Finally, we observed that a concurrent decline in SARS-CoV-2 specific cellular and
258 humoral immunity and prolonged SARS-CoV-2 exposure predicted fatal outcomes. There was

259 significant correlation between SARS-CoV-2 specific T cell immunity and SARS-CoV-2 specific
260 humoral immunity. The frequency of SARS-CoV-2 specific T cells and titer of IgG were much
261 lower than that of survival patients with COVID-19 and there were high viral load in the course of
262 the disease, indicating that the persistent SARS-CoV-2 infection and the loss expansion of
263 SARS-CoV-2 specific immunity.

264 **Acknowledgments**

265 The work was supported in part by the National Natural Science Foundation of China (Grant No.
266 81830052 and 81530053).

267 **Author contributions**

268 [#]Drs. Q Zeng, G Huang and YZ Li contributed equally to this article and share first authorship.

269 * Correspondence to Dr. Y Xu.

270

271 Q Zeng, G Huang and YZ Li contributed to study design, data interpretation, and manuscript
272 drafting. GX, ZTC, ZTC contributed to data analysis, figure preparation, the literature search, and
273 manuscript drafting. SYD and GX contributed to performed experiments, data collection, data
274 analysis, and figure preparation. YX contributed to study design and reviewed the final draft. All
275 authors read and approved the manuscript.

276

277 **Competing interests statement**

278 We declare no competing interests.

279

280

281

282 **References**

- 283 1. Zhu, N., *et al.* A novel coronavirus from patients with pneumonia in China, 2019. *N. Engl.J.*
284 *Med.* **382**, 727-733 (2020).
- 285 2. Huang, C., *et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan,
286 China. *Lancet (London, England)* **395**, 497-506 (2020).
- 287 3. Guan, W.J., *et al.* Clinical characteristics of coronavirus disease 2019 in China. *N. Engl.J.*
288 *Med.* **382**, 1708-1720 (2020).
- 289 4. Li, Q., *et al.* Early transmission dynamics in Wuhan, China, of novel coronavirus-infected
290 pneumonia. *N. Engl.J. Med.* **382**, 1199-1207 (2020).
- 291 5. Wang, D., *et al.* Clinical characteristics of 138 hospitalized patients with 2019 novel
292 coronavirus-infected pneumonia in Wuhan, China. *JAMA* **323**, 1061-1069 (2020).
- 293 6. Zhou, F., *et al.* Clinical course and risk factors for mortality of adult in patients with
294 COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet (London, England)* **395**,
295 1054-1062 (2020).
- 296 7. Wu, C., *et al.* Risk factors associated with acute respiratory distress syndrome and death in
297 patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern. Med.*, doi:
298 10.1001/jamainternmed.2020.0994 (2020).
- 299 8. Wrapp, D., *et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.
300 *Science (New York, N.Y.)* **367**, 1260-1263 (2020).
- 301 9. Yan, R., *et al.* Structural basis for the recognition of SARS-CoV-2 by full-length human
302 ACE2. *Science (New York, N.Y.)* **367**, 1444-1448 (2020).

- 303 10. Hamming, I., *et al.* Tissue distribution of ACE2 protein, the functional receptor for SARS
304 coronavirus. A first step in understanding SARS pathogenesis. *J. Pathol.* **203**, 631-637
305 (2004).
- 306 11. World Health Organization. Clinical management of severe acute respiratory infection when
307 novel coronavirus (nCoV) infection is suspected. *Interim guidance on January 12, 2020*
308 (*accessed February 15*), <https://apps.who.int/iris/handle/10665/330854> (2020).
- 309 12. Pan, X., *et al.* Asymptomatic cases in a family cluster with SARS-CoV-2 infection. *Lancet*
310 *Infect. Dis.* **20**, 410-411 (2020).
- 311 13. Rothe, C., *et al.* Transmission of 2019-nCoV infection from an asymptomatic contact in
312 Germany. *N. Engl.J. Med.* **382**, 970-971 (2020).
- 313 14. WHO. Rolling updates on coronavirus disease (COVID-19). .
314 <https://www.who.int/emergencies/diseases/novel-coronavirus-2019> (*accessed June 29, 2020*)
315 (2020).
- 316 15. Xu, Z., *et al.* Pathological findings of COVID-19 associated with acute respiratory distress
317 syndrome. *Lancet Respir. Med.* **8**, 420-422 (2020).
- 318 16. Vabret, N., *et al.* Immunology of COVID-19: Current State of the Science. *Immunity* **52**,
319 910-941 (2020).
- 320 17. Diao, B., *et al.* Reduction and functional exhaustion of T cells in patients with coronavirus
321 disease 2019 (COVID-19). *Front. Immunol.* **11**, 827 (2020).
- 322 18. Ni, L., *et al.* Detection of SARS-CoV-2-specific humoral and cellular immunity in
323 COVID-19 convalescent individuals. *Immunity* **52**, 971-977.e973 (2020).
- 324 19. Giamarellos-Bourboulis, E.J., *et al.* Complex immune dysregulation in COVID-19 patients

- 325 with severe respiratory failure. *Cell Host Microbe* **27**, 992-1000.e1003 (2020).
- 326 20. Day, C.L., *et al.* PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion
327 and disease progression. *Nature* **443**, 350-354 (2006).
- 328 21. Trautmann, L., *et al.* Upregulation of PD-1 expression on HIV-specific CD8⁺ T cells leads to
329 reversible immune dysfunction. *Nat. Med.* **12**, 1198-1202 (2006).
- 330 22. Grifoni, A., *et al.* Targets of T cell responses to SARS-CoV-2 coronavirus in humans with
331 COVID-19 disease and unexposed individuals. *Cell* **181**, 1489-1501.e1415 (2020).
- 332 23. Chen, G., *et al.* Clinical and immunological features of severe and moderate coronavirus
333 disease 2019. *J. Clin. Invest.* **130**, 2620-2629 (2020).
- 334 24. Liu, J., *et al.* Longitudinal characteristics of lymphocyte responses and cytokine profiles in
335 the peripheral blood of SARS-CoV-2 infected patients. *EBioMedicine* **55**, 102763 (2020).
- 336 25. Tan, L., *et al.* Lymphopenia predicts disease severity of COVID-19: a descriptive and
337 predictive study. *Signal. Transduct. Target. Ther.* **5**, 33 (2020).
- 338 26. Wang, F., *et al.* Characteristics of peripheral lymphocyte subset alteration in COVID-19
339 pneumonia. *J. Infect. Dis.* **221**, 1762-1769 (2020).
- 340 27. Channappanavar, R., Fett, C., Zhao, J., Meyerholz, D.K. & Perlman, S. Virus-specific
341 memory CD8 T cells provide substantial protection from lethal severe acute respiratory
342 syndrome coronavirus infection. *J. Virol.* **88**, 11034-11044 (2014).

343

344

345

346

347

348 **Figures and Legends**

349

350 Figure 1. Dynamic distribution of lymphocytes and subsets related to age in 25,239 health controls.

351 We enrolled laboratory data from 25,239 health controls aged from 16-91 years old in November

352 2017 and November 2019 from health check up before the COVID-19 pandemic.

353

354 Figure 2. Dynamic distribution of SARS-CoV-2 specific immunity and viral load related to age in

355 fatal cases.

356

357 Figure 3. Dynamic distribution of SARS-CoV-2 specific immunity and viral load related to

358 survival time in fatal cases.

359

360 Figure 4. Dynamic characteristics of SARS-CoV-2 specific immunity and viral load in fatal cases.

361 ns, $P > 0.05$; *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$; ****, $P < 0.0001$.

362

363 Figure 5. PBMCs of 21 fatal cases at week 3 were stimulated with SARS-CoV-2 Spike

364 glycoprotein peptide pools (SPs). The graph showed the percentage of SARS-CoV-2 specific

365 IFN γ +CD4+T cells (A) and SARS-CoV-2 specific IFN γ +CD8+ T cells (B) reactive to the SPs

366 directly *ex vivo* (w/o expansion) and after *in vitro* expansion (expansion). **, $P=0.0017$; ****,

367 $P<0.0001$.

368

369 Figure 6. SARS-CoV-2 specific T cell immunity (IFN γ +CD8+ and IFN γ +CD4+) did not correlate
370 with SARS-CoV-2 specific humoral immunity.

371

372 Figure 7. SARS-CoV-2 specific T cell immunity (IFN γ +CD8+ and IFN γ +CD4+) inversely
373 correlated with SARS-CoV-2 viral load.

374

375 Figure 8. SARS-CoV-2 specific humoral immunity (IgG) inversely correlated with SARS-CoV-2
376 viral load.

377

378 Figure 9. SARS-CoV-2 specific immunity of 21 fatal cases and 18 survival cases at week 3 were
379 compared. The graph showed the percentage of SARS-CoV-2 specific IFN γ +CD4+T cells (A),
380 SARS-CoV-2 specific IFN γ +CD8+ T cells (B) and IgG titers (C). ****, $P < 0.0001$.

381

382

383

384

385

386

387

388

389

390

391




Figure 1

392

393




Figure 2

394




Figure 3

395




Figure 4

396

397




Figure 5

398

399





Figure 6


400

401



402

403



404

405




Figure 9

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420 **Supplemental Materials**


421

422 **Table S1. Demographic characteristics of 35 fatal patients with COVID-19 on admission**

Characteristics	Patients
Age, Median (IRQ), years	64.0 (45.0-73.0)
Gender	
Male	24 (68.6%)
Female	11 (31.4%)
Comorbidities	
Hypertension	11 (31.4%)
Cardiovascular diseases	7 (20.0%)
Diabetes	6 (17.1%)
Main symptoms	
Fever	30 (85.7%)
Cough	18 (51.4%)
Fatigue	6 (17.1%)

423

424



425

426 **Figure S1. A representative flow cytometry gating strategy.**

427

428 EXPERIMENTAL MODEL AND SUBJECT DETAILS

429 **Study Design and Participants**

430 This retrospective study was conducted at Chinese PLA General Hospital, Peking Union Medical
431 College Hospital, the First Affiliated Hospital, and affiliated hospitals of Shanghai University of
432 Medicine and Health Sciences. Chinese PLA General Hospital and Peking Union Medical College
433 Hospital are the largest clinical research hospitals in China. Demographic characteristics of 35
434 fatal patients with COVID-19 on admission were listed in Table S1. The 18 severe or critical cases
435 (matched by age and sex) that survived were enrolled for comparison. This case series was
436 approved by the institutional ethics board of Chinese PLA General Hospital (#2020-111), Peking
437 Union Medical College Hospital (#ZS-1830), The First Affiliated Hospital (#KY2020046), and
438 Shanghai University of Medicine and Health Sciences (#2019-LCHZ-18-20190507). Written
439 informed consent was obtained from healthy controls and waived to COVID-19 patients due to the
440 rapid emergence of this infectious disease. Identification of hypertensive patients was achieved by
441 reviewing and analyzing available electronic medical records and patient care resources. Clinical
442 outcomes (discharge, mortality, and recovery, etc.) were monitored and all clinical recovery
443 hypertensive patients meet the following criteria: body temperature returned to normal for more
444 than 3 days, respiratory symptoms improved significantly, and lung imaging showed significant
445 improvement.

446 METHOD DETAILS

447 **Cell preparation**

448 Whole blood was centrifuged for 15 min at 1800 rpm to separate the cellular fraction and plasma.
449 The plasma was then carefully removed from the cell pellet and stored at -20°C. Peripheral blood

450 mononuclear cells (PBMCs) were isolated using Ficoll-Paque PLUS density gradients (GE
451 Healthcare Life Sciences, USA) according to the manufacturer's instructions. Isolated PBMCs
452 were either studied directly or cryopreserved in cell recovery media containing 10% DMSO
453 (Gibco, USA), supplemented with 10% heat inactivated fetal bovine serum and stored in liquid
454 nitrogen until used in the assays. Cryopreserved PBMCs were thawed by diluting them in 10 mL
455 complete RPMI 1640 with 5% human AB serum (Gemini Bioproducts, USA) in the presence of
456 benzonase (final concentration at 50 U/mL) before an experiment.

457 **SARS-CoV-2 Spike glycoprotein peptide pools**

458 SARS-CoV-2 Spike glycoprotein peptide pools (SPs) were from Genscript Biotech, USA. SPs
459 include 316 peptides (delivered in two subpools of 158 peptides) derived from a peptide scan (15
460 mers with 11 amino acid overlap) through the entire Spike glycoprotein of SARS-CoV-2.

461 **Expansion of PBMCs *in vitro***

462 20% of PBMCs were pulsed with 10 µg/mL of the SPs for 1 hour at 37 °C, subsequently washed,
463 and cocultured with the remaining cells in AIM-V medium (Gibco; Thermo Fisher Scientific,
464 USA) supplemented with 2% AB human serum (Gibco; Thermo Fisher Scientific, USA). PBMCs
465 were cultured for 7 days in the presence of 20 U/mL of recombinant IL-2 (R&D Systems, USA).

466 **Intracellular cytokine staining (ICS) assay**

467 PBMCs were first stimulated with or without SPs (2 µg /mL) for 3 h at 37°C, then brefeldin A (10
468 µg/mL, Sigma-Aldrich, USA) was added to cultures to enable intracellular proteins to accumulate
469 in all stimulations. PBMCs were stimulated RPMI medium containing 10% FCS as a negative
470 control. After incubation for a total of 6 h, the cells were washed, fixed, permeabilized using
471 fixation/permeabilization solution kit (BD Biosciences, USA) and blocked with FcR blocking

472 reagent (Meltanyi Biotec, USA) for 30 min at 4 °C to reduce nonspecific binding of antibodies to
473 human Fc receptor. The cells were then stained with anti-IFN γ antibodies (BD Bioscience, USA)
474 for 30 min at 4 °C. After staining, all samples were washed twice with phosphate buffered saline
475 (PBS) containing 0.1% saponin, 0.1% BSA and 0.05% NaN₃ (Sigma-Aldrich, USA), and
476 resuspended in 300 μ L PBS for measurement in a flow cytometer (FACSVerse™ flow cytometry,
477 BD Bioscience, USA).

478 **Real-time reverse transcription polymerase chain reaction (RT-PCR) assay for SARS-CoV-2**

479 Throat, sputum and blood samples were collected for extracting SARS-CoV-2 RNA from
480 hypertensive patients suspected of having SARS-CoV-2 infection. In brief, RNA was extracted
481 within 2 h using the total RNA isolation kit. Cell lysates (250 μ L) were transferred into a
482 collection tube followed by vortex for 10 s. After standing at room temperature for 10 min, the
483 collection tube was centrifugated at 1000 rpm for 5 min. The suspension was used for RT-PCR
484 assay of SARS-CoV-2 RNA. Two target genes, including open reading frame 1ab (ORF1ab) and
485 nucleocapsid protein (N), were simultaneously amplified and tested during the RT-PCR assay.
486 The sequences of primers and probes were: Target 1 (ORF1ab): forward primer
487 CCCTGTGGGTTTTACTTAA; reverse primer ACGATTGTGCATCAGCTGA; and the probe
488 5'-VIC-CCGTCTGCGGTATGTGGAAAGGTTATGG-BHQ1-3'. Target 2 (N): forward primer
489 GGGGAAGTTCCTGCTAGAAT; reverse primer CAGACATTTGCTCTCAAGCTG; and
490 the probe 5'-FAM-TTGCTGCTGCTTGACAGATT-TAMRA-3'. The RT-PCR assay was
491 performed using a SARS-CoV-2 nucleic acid detection kit. Reaction mixture contained 12 μ L of
492 reaction buffer, 4 μ L of enzyme solution, 4 μ L of probe primer solution, 3 μ L of diethyl
493 pyrocarbonate-treated water, and 2 μ L of RNA template. The RT-PCR assay was performed

494 under the following conditions: incubation at 50 °C for 15 min and 95 °C for 5 min, 40 cycles of
495 denaturation at 94 °C for 15 s, and extending and collecting fluorescence signal at 55 °C for 45 s.
496 A cycle threshold value (C_t -value) less than 37 was defined as a positive test result, and a C_t -value
497 of 40 or more was defined as a negative test. These diagnostic criteria were based on the
498 recommendation by the National Institute for Viral Disease Control and Prevention (China).
499 Samples with a C_t -value of 37 to less than 40 was confirmation by retesting. The copies of RNA
500 per reaction were obtained from the standard curve of limiting-dilution series of standard copies of
501 RNA versus PCR amplification cycle.

502 **Enzyme-linked immunosorbent assay (ELISA) of immunoglobulin (Ig)**

503 Antibodies (IgM, IgA, and IgG) specific to SARS-CoV-2 were determined with two different
504 ELISA: an in-house assay using SARS-CoV-2 Receptor Binding Domain (RBD) protein (Cat.
505 #Z03479, Genscript Biotech, USA) as an antigen, or a commercial kit (SARS-CoV-2 Spike RBD
506 ELISA Kit, Cat. #40591-V08H, Sino Biological, China). Microtiter plates were coated with 50
507 ng/well of target protein overnight at 4 °C. Plates were then blocked for 2 h at 37 °C using 200 μ L
508 of 5% non-fat milk in PBS. Serum samples were then diluted into 1:50 using PBS and 100 μ L of
509 each sample was applied to coated ELISA plate and incubated for 2 h at 37 °C. Plates were then
510 washed with PBS and incubated with HRP-labeled anti-human IgM, IgA, and IgG (Sigma Aldrich,
511 USA), which were diluted to 1:2000 in 5% non-fat milk in PBS. After incubation for another 1 h
512 at room temperature, the plates were washed and developed with TMB/E substrate (Millipore,
513 USA). Finally, the reaction was stopped with 1 M H_2SO_4 , and the optical density (OD) at 450 nm
514 was measured. Negative serum control was run each time when the assay was performed. A
515 sample is positive if its adjusted OD value (OD of test – OD of control) exceeds the mean plus 3

516 standard deviations of the normal controls.

517 **Flow cytometry analysis**

518 All samples were analyzed by FACSVerse™ flow cytometry (BD Bioscience, USA). Two blood

519 samples in two tubes (100 µL each) were stained according to the manufacturer's instructions.

520 Then, red-cell lysis buffer (1 mL) was added to each tube, the samples were incubated for 10 min

521 and washed with Sorvall cell washer (Thermo Fisher Scientific, USA). Cells were blocked with

522 FcR blocking reagent (Milty Biotech, USA) for 30 min at 4 °C to reduce nonspecific binding of

523 antibodies to human Fc receptor and washed with PBS. The cells were then stained with

524 antibodies as listed in Figure and the fixable dead cell stain kit (Invitrogen, USA) for 30 min at

525 4 °C and were then resuspended in 350 µL PBS and analyzed in flow cytometry (FACSVerse™

526 flow cytometry, BD Bioscience, USA). Calibration and quality control for the instrument were

527 carried out daily with the use of eight-color setup beads (BD Bioscience). All specimens were

528 analyzed in duplicates with coefficient of variation (CV) < 5% by two independent technicians

529 under the inter-laboratory quality control. The experiments were repeated if the results showed

530 CV > 5% according to the instructions of BD Bioscience. The data were analyzed by FlowJo

531 software (version 10, Tree Star, USA).

532 **Statistical analysis**

533 Categorical variables were described as frequency rates and percentages, and continuous variables

534 were described using mean and median values. Means for continuous variables were compared

535 using independent group *t* tests when the data were normally distributed; otherwise, the

536 Mann-Whitney test was used. Data (non-normal distribution) from repeated measures were

537 compared using the generalized linear mixed model. Proportions for categorical variables were

538 compared using the χ^2 test, although the Fisher's exact test was used when the data were limited.

539 All statistical analyses were performed using SPSS (Statistical Package for the Social Sciences

540 Inc., version 13.0). For unadjusted comparisons, a two-sided *P* value less than 0.05 was

541 considered statistically significant. The analyses have not been adjusted for multiple comparisons

542 and, given the potential for type I error, the findings should be interpreted as exploratory and

543 descriptive. Because the cohort of patients in our study was not derived from random selection, all

544 statistics are deemed to be descriptive only.

545

546